Related Experiment Video
Updated: Jul 4, 2026

Multiomics Analysis of TMEM200A as a Pan-Cancer Biomarker
Published on: September 15, 2023
In good times and bad: p73 in cancer
Claudia Oswald1, Thorsten Stiewe
1Department for Hematology, Oncology and Immunology, Institute for Molecular Biology and Tumor Research, Philipps-University Marburg, Marburg, Germany.
Abstract:
It is widely accepted in cancer biology that p53 has a tumor suppressive activity, which is lost during tumorigenesis most frequently by mutations in the p53 gene. The discovery of p73 as the first homologue of p53 raised immediate expectations about p53-like tumor suppressor activities. Although tumors show changes in the expression level of p73 and differences in the expression pattern of p73 isoforms, mutations are not commonly observed making it difficult to infer p73's role in tumorigenesis. An experimental model of human cell transformation closely mimics the expression changes observed in cancer patients and provides novel insights into the regulation and function of p73 in the various steps on the road to malignant transformation. p53-like isoforms of p73 (TAp73) are upregulated early during the transformation process in response to RB pathway alterations and block progression to the fully transformed state. Antagonists of TAp73 such as the dominant-negative p73 protein DeltaNp73 overcome this block and pave the way to full transformation. Here we review these findings in the context of patient data and recent advances on molecular aspects of p73 function and discuss the implications for p73 as a target for cancer therapy.
Insights
The tumor suppressor p73 (p73) and its p53-like isoforms (TAp73) initially block cancer progression. However, antagonists like DeltaNp73 promote full transformation, highlighting p73
Area of Science:
- Cancer Biology
- Molecular Oncology
- Tumorigenesis Research
Background:
- The tumor suppressor p53 is frequently inactivated in cancer, leading to research into its homologue, p73.
- While p73 expression changes in tumors, mutations are rare, complicating its role in cancer development.
- Understanding p73's function is crucial for cancer therapy development.
Purpose of the Study:
- To investigate the role of p73 and its isoforms in human cell transformation.
- To elucidate the regulatory mechanisms and functional significance of p73 during tumorigenesis.
- To explore p73 as a potential therapeutic target in cancer treatment.
Main Methods:
- Utilized an experimental model of human cell transformation.
- Analyzed expression changes of p73 and its isoforms.
- Correlated findings with patient data and molecular insights.
Main Results:
- p53-like p73 isoforms (TAp73) are upregulated early in transformation, driven by RB pathway alterations.
- TAp73 acts to block progression to a fully transformed state.
- Dominant-negative p73 (DeltaNp73) antagonizes TAp73, facilitating full transformation.
Conclusions:
- TAp73 functions as a tumor suppressor early in transformation.
- DeltaNp73 acts as an antagonist, promoting malignant progression.
- p73 and its isoforms represent promising therapeutic targets for cancer intervention.
Related Concept Videos
Cancer
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
What is Cancer?
Although people have known about cancer for centuries, it was only in 1761 that Giovanni Morgagni of Padua performed a detailed autopsy of patients who died from...
What is Cancer?
Although people have known about cancer for centuries, it was only in 1761 that Giovanni Morgagni of Padua performed a detailed autopsy of patients who died from...
Abnormal Proliferation